1. Scrip

US/China-based MicuRx Gets $55m Series C Funding For MRX-I Antibiotic

 
• By Sten Stovall

Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $55 million in a Series C venture capital round to fund further clinical trials in the US for its next-generation oral oxazolidinone MRX-I through to the drug’s first New Drug Application filing in China.

US-Money-and-Pills_V2_1200x675

MicuRx Pharmaceuticals Inc.’s latest financing exercise – a Series C financing - brought it $55m which the Sino-US drug developer will use to progress its lead drug candidate, MRX-I, an oral oxazolidinone antibiotic currently in Phase III China trials.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia